Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Hanover Media Strategy Limited .
Filed returns
110
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Jan–Apr 2023 | Hanover Media Strategy Limited | Health | The landscape for innovative and precision medicines in Ireland. (Public policy or programme) | 12 | On lobbying.ie |
| Jan–Apr 2023 | Hanover Media Strategy Limited | Health | Ireland's readiness for the rollout of radioligand therapy (Public policy or programme) | 12 | On lobbying.ie |
| Jan–Apr 2023 | Hanover Media Strategy Limited | Health | EU regulation on substances of human origin (Legislation) | 2 | On lobbying.ie |
| Jan–Apr 2023 | Hanover Media Strategy Limited | Health | Rare Disease Policy (Legislation) | 17 | On lobbying.ie |
| Sep–Dec 2022 | Hanover Media Strategy Limited | Health | Briefing on AstraZeneca's operations in Ireland. (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2022 | Hanover Media Strategy Limited | Health | Request for a meeting to discuss the landscape for innovative and precision medicines in Ireland. (Public policy or programme) | 18 | On lobbying.ie |
| Sep–Dec 2022 | Hanover Media Strategy Limited | Health | Rare Disease Policy (Legislation) | 9 | On lobbying.ie |
| May–Aug 2022 | Hanover Media Strategy Limited | Health | Briefing on AstraZeneca's operations in Ireland. (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2022 | Hanover Media Strategy Limited | Health | Visit to the Alexion, AstraZeneca Rare Disease facility in Athlone. (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2022 | Hanover Media Strategy Limited | Health | Meeting to discuss the reimbursement landscape and access challenges for personalised medicines in Ireland. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2022 | Hanover Media Strategy Limited | Health | Introducing Horizon and its presence in Ireland (Public policy or programme) | 16 | On lobbying.ie |
| Jan–Apr 2022 | Hanover Media Strategy Limited | Health | Update on AstraZeneca sponsored roundtable outcomes held for Chronic Obstructive Pulmonary Disease (Public policy or programme) | 14 | On lobbying.ie |
| Sep–Dec 2021 | Hanover Media Strategy Limited | Health | Partnership for Health System Sustainability and Resilience (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2021 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 4 | On lobbying.ie |
| Sep–Dec 2021 | Hanover Media Strategy Limited | Health | Update on AstraZeneca COVID-19 vaccine and therapies (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2021 | Hanover Media Strategy Limited | Health | Update on COVID-19 Vaccine AstraZeneca (Public policy or programme) | 8 | On lobbying.ie |
| May–Aug 2021 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 9 | On lobbying.ie |
| May–Aug 2021 | Hanover Media Strategy Limited | Health | Medicines Access for Irish patients with rare diseases (Legislation) | 1 | On lobbying.ie |
| May–Aug 2021 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 9 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Health | Update on COVID-19 Vaccine AstraZeneca (Public policy or programme) | 15 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 15 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 9 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Engagement on National Screening Advisory Committee Bill 2020 and the newborn screening programme (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Centralised Services for Rare Disease Medicines (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 14 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Provided update to select politicians on developments in Oncology therapies and barriers to access (Matters involving public funds) | 4 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Briefed select parliamentarians on potential Covid-19 vaccine (Public policy or programme) | 22 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 10 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | Update on potential COVID-19 Vaccine (Matters involving public funds) | 4 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 10 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 16 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | Optimisation of Rheumatoid Arthritis pathway of care (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 5 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 4 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | Optimisation of Rheumatoid Arthritis pathway of care (Matters involving public funds) | 10 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 8 | On lobbying.ie |
| Sep–Dec 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 2 | On lobbying.ie |
| Sep–Dec 2019 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) | 7 | On lobbying.ie |
| May–Aug 2019 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 4 | On lobbying.ie |
| May–Aug 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) | 15 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Health | Engaged Government Ministers on patient safety, STEM education and healthcare innovation (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 5 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 10 | On lobbying.ie |
| Sep–Dec 2018 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 10 | On lobbying.ie |
| May–Aug 2018 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 13 | On lobbying.ie |
| Jan–Apr 2018 | Hanover Media Strategy Limited | Health | Reimbursement of Vimizim for Morquio A Syndrome (Matters involving public funds) | 12 | On lobbying.ie |
| Jan–Apr 2018 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 12 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Vimizim for Morquio A Syndome (Matters involving public funds) | 16 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 110 | 100.0% |